Charles River Laboratories International, Inc.

New York Stock Exchange
Back to all articles
Bullish +55

Charles River Labs stock rises as management signals growth inflection

AI-generated analysis

📈 Charles River Laboratories stock has gained over 20% in the past year as management signals a growth inflection starting in the second half of 2026.

💰 The company expects manufacturing margins to approach 40% and generates at least USD 500 million in annual free cash flow in normal years.

🔬 Drug Safety Assessment (DSA) posted a book-to-bill ratio of 1.19 in Q2 2026, the highest level in four years, with revenue expected to accelerate later this year.

📊 Microbial Solutions delivered high single-digit organic growth in Q2 2026 and is expected to remain a solid contributor to overall performance.

⚠️ The Research Models and Services (RMS) segment is projected to experience a low single-digit revenue decline for full-year 2026.

💸 Year-to-date in 2026, the company has deployed about USD 800 million in capital, including USD 500 million for acquisitions and USD 300 million for buybacks.

📉 Recent quarterly performance shows the stock returned about 0.29% over the last quarter and minus 1.46% year-to-date despite annual gains.

🏦 Charles River Laboratories maintains a net debt to EBITDA leverage ratio of approximately 2.5 times as of mid-September 2026.

💵 The stock trades at a market capitalization of about USD 13.28 billion with an AI-based price target of USD 276.92.

Bullish Signals
  • Charles River Laboratories expects manufacturing margins to expand to near 40% in the second half of 2026, up from the upper 30s range seen in Q2.
  • The Drug Safety Assessment segment achieved a book-to-bill ratio of 1.19 in Q2 2026, its highest level in four years, indicating strong order intake.
  • Management raised free cash flow guidance to at least USD 500 million annually in normal years, supporting acquisition spending and share repurchases.
  • The Microbial Solutions segment delivered high single-digit organic growth in Q2 2026 and is expected to remain a solid contributor.
  • Shares have gained over 20% over the past year as investors react to management's signals of stabilization and growth inflection.
Risk Factors
  • Recent stock performance has been flat or slightly negative, with the share returning minus 1.46% year-to-date in 2026.
  • The company's recent quarterly return was only 0.29%, indicating a lack of immediate momentum despite annual gains.
Full Analysis
Charles River Laboratories International, Inc. (CRL) shares have appreciated over 20% in the past year as management signaled a strategic inflection point at a September 2026 investor conference. The company projects manufacturing margins expanding to approximately 40% and expects annual free cash flow generation of at least USD 500 million during normal years, supporting continued capital deployment for acquisitions and share repurchases. Key drivers for this recovery include the Drug Safety Assessment (DSA) segment, which posted a book-to-bill ratio of 1.19 in Q2 2026, its highest level in four years. Management anticipates revenue acceleration in DSA during the second half of 2026 following modest growth in the quarter, while the Microbial Solutions segment continues to deliver high single-digit organic growth. Despite these positive trends, the Research Models and Services (RMS) business is expected to face a low single-digit revenue decline for full-year 2026. Investors are monitoring the stabilization of RMS relative to the stronger performance in DSA and Manufacturing. As of mid-September 2026, the company has deployed roughly USD 800 million in capital year-to-date while maintaining a net debt to EBITDA leverage ratio of about 2.5 times. Recent stock performance data indicates that while CRL gained about 21.55% over the last year, recent quarterly returns have been relatively flat or slightly negative. The company trades at a market capitalization of approximately USD 13.28 billion with an AI-based price target suggesting limited immediate upside from current levels.